Ultra-Low Stimulation in Sacral Neuromodulation: A Game-Changer for Faecal Incontinence Treatment

Could Ultra-Low Stimulation Transform Faecal Incontinence Treatment?

# Ultra-Low Stimulation in Sacral Neuromodulation Proves Effective for Faecal Incontinence Treatment

A groundbreaking randomized, double-blind, multicentre study has demonstrated that sacral neuromodulation (SNM) with ultra-low stimulation amplitude is as effective as conventional higher amplitude stimulation for patients with faecal incontinence (FI). This finding could significantly impact treatment approaches, patient comfort, and long-term device management for the estimated 16% of the population affected by this condition.

Faecal incontinence represents a significant healthcare challenge, often described as a 'silent affliction' due to underreporting by patients reluctant to discuss their symptoms with healthcare providers. The condition substantially impacts quality of life and carries considerable stigma for affected individuals and their families. Current management guidelines recommend starting with conservative treatments such as fibre supplements, constipating medications, biofeedback therapy, or transanal irrigation, with sacral neuromodulation considered when these approaches prove insufficient.

How Was This Groundbreaking Study Designed?

The study, conducted across three tertiary referral centres in Denmark and Norway, included 73 patients (70 female) with a median age of 60 years who had either idiopathic FI or FI due to an external anal sphincter defect of ≤160°. All participants had previously attempted maximal conservative therapy without satisfactory results. The researchers employed a one-stage implantation procedure using a Medtronic Model 3889 quadripolar lead and InterStim-II neurostimulator, with specific perioperative inclusion criteria requiring motor response in three or more poles of the quadripolar lead with at least one pole demonstrating a motor threshold ≤1.5 mAmp.

Patients were randomized into two groups the day after surgery. Group 1 (G-1) received a progressive stimulation protocol starting with ultra-low stimulation at 0.05 volts (equivalent to approximately 9.6% of sensory threshold) for weeks 1-4, then increased to 50% of sensory threshold for weeks 5-8, and finally to 90% of sensory threshold for weeks 9-12. Group 2 (G-2) received consistent stimulation at 90% of sensory threshold throughout the first 12 weeks. Both groups then received stimulation at full sensory threshold for weeks 13-24.

How Effective Is Ultra-Low Stimulation?

The results revealed that even at the ultra-low stimulation amplitude of 0.05 volts, patients experienced significant improvement in symptoms. During the first 4 weeks, G-1 patients showed a median 78% reduction in FI episodes compared to 71% in G-2, with no statistically significant difference between groups. The only parameter showing a significant difference was the visual analogue scale (VAS) for bowel function, where G-2 patients reported a median improvement of 50 points compared to 30 points in G-1 (p=0.05). However, researchers noted this isolated finding might represent a type I statistical error rather than a true clinical difference.

When examining the overall results at the 24-week follow-up, the effectiveness of the treatment was remarkable across both groups. The median reduction in incontinence episodes compared to baseline was 87.5%, with 92% of patients achieving a 50% or greater reduction in episodes. Perhaps most impressively, 33% of participants reported complete resolution of FI episodes. The St. Mark's Incontinence Score was significantly reduced from baseline by a median of 6 points, while patient satisfaction with bowel function improved by a median of 50 points on the VAS scale.

What Are the Clinical Implications and Limitations?

These findings challenge previous assumptions about the minimum stimulation threshold needed for effective neuromodulation. The researchers had initially expected the 0.05 volt setting to be equivalent to just 2-5% of sensory threshold, potentially serving as a placebo-like intervention. However, the observed sensory thresholds were lower than anticipated, resulting in the ultra-low setting being approximately 9.6% of threshold. The effectiveness of this ultra-low amplitude suggests that even minimal electrical stimulation may be sufficient to activate the ion channels responsible for nerve modulation.

The implications of these results are substantial for clinical practice. Using ultra-low stimulation could significantly reduce patient discomfort associated with sensory-level stimulation while extending neurostimulator battery life and potentially lowering long-term treatment costs. Additionally, the reduced energy delivery to surrounding tissue might theoretically decrease the risk of nerve damage, although this would require further investigation.

The study does acknowledge certain limitations, including the lack of a specific sample size calculation for the randomized component and the absence of a washout period before starting the trial, which might have influenced results through a potential carry-over effect from the electrical stimulation used during lead placement. Furthermore, the strict inclusion criteria may limit the transferability of results to broader clinical practice, and the 24-week follow-up period does not address questions about long-term efficacy of subsensory stimulation.

Could these findings fundamentally change how we approach stimulation parameters in sacral neuromodulation for faecal incontinence? The potential for achieving equivalent clinical outcomes with significantly reduced stimulation intensity represents an important advancement in the field. Beyond the immediate benefits for patient comfort, what implications might this have for the longevity of implanted devices and the overall cost-effectiveness of this treatment approach? Additionally, what neurophysiological mechanisms might explain the effectiveness of such minimal stimulation, and how might this inform our understanding of neuromodulation more broadly?

As the first study to document the effectiveness of ultra-low stimulation amplitude in newly implanted SNM patients with faecal incontinence, this research opens promising avenues for optimizing treatment protocols. Further investigation with larger patient populations and longer follow-up periods will be essential to confirm these encouraging initial results and potentially reshape clinical practice guidelines for this challenging condition.

Summary

A pioneering randomized, double-blind, multicentre study has demonstrated that sacral neuromodulation using ultra-low stimulation amplitude (0.05 volts, approximately 9.6% of sensory threshold) is as effective as conventional higher amplitude stimulation for treating faecal incontinence. The research, conducted across three tertiary referral centres in Denmark and Norway, included 73 patients who had failed conservative therapy. Patients receiving ultra-low stimulation during the initial four weeks showed a median 78% reduction in incontinence episodes, comparable to the 71% reduction in patients receiving conventional 90% sensory threshold stimulation. At 24-week follow-up, both groups demonstrated remarkable outcomes, with a median 87.5% reduction in incontinence episodes, 92% of patients achieving at least 50% symptom improvement, and 33% experiencing complete resolution. These findings challenge previous assumptions about minimum effective stimulation thresholds and suggest that minimal electrical stimulation may sufficiently activate the ion channels responsible for nerve modulation. The clinical implications are substantial, potentially offering reduced patient discomfort, extended neurostimulator battery life, lower long-term treatment costs, and possibly decreased risk of nerve damage. While the study acknowledges limitations including relatively short follow-up duration and strict inclusion criteria, it represents the first documentation of ultra-low stimulation effectiveness in newly implanted sacral neuromodulation patients with faecal incontinence, opening promising avenues for optimizing treatment protocols for this condition affecting approximately 16% of the population.